Johnson & Johnson reported a solid quarter with 6% sales growth and strong oncology business expansion, despite a slight miss in MedTech. Analysts maintain a bullish outlook with a 12-month price target of $291.60, implying a 15.6% upside from current levels. The company’s long history of dividend increases and diversified portfolio support its defensive stock status. Key growth drivers include the TREMFYA franchise and oncology segment, while risks involve recent deal dilution and MedTech performance. The stock trades at a premium compared to peers but offers stability and growth potential for investors.
Johnson & Johnson's reputation as a defensive stock aligns with its current trading status on Pluang, where it is priced at USD 253.79 as of Oct 19, 2026, 18:12 WIB. The stock has seen a slight dip of 0.69% in one day but maintains a dividend yield of 2.1%, reflecting its appeal for income-focused investors. With a market cap of $615.87 billion and a 52-week high of $278.43, JNJ remains a significant player in the health sector on Pluang.
Johnson & Johnson announced that TREMFYA (guselkumab) maintained or improved fistula remission in adults with Crohn's disease through 48 weeks in the Phase 3 FUZION study. The combined fistula remission rate increased from 28% at Week 24 to 35% at We...
Jim Cramer and financial analysts recommend investors diversify portfolios with stable, dividend-paying stocks like consumer staples, pharmaceuticals, and waste management to protect against tech sector downturns. These 'quiet winners' continue to de...
Johnson & Johnson's recent quarterly report showed its MedTech segment sales fell short of Wall Street expectations, primarily due to pricing pressures in China and budget cuts in Europe. This shortfall caused the company's shares to decline, impacti...
